This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Xiong, C. Articles by Zhang, Z. Search for Related Content PubMed PubMed Citation Articles by Xiong, C. Articles by Zhang, Z. Social Bookmarking                         What's this?

Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial

Division of Biostatistics, Campus Box 8067, Washington University in St Louis, St Louis, MO 63110, USA; chengjie{at}wubios.wustl.edu

Kai Yu

Feng Gao

Division of Biostatistics, Washington University in St Louis, St Louis, MO, USA

Yan Yan

Division of Biostatistics, Washington University in St Louis, St Louis, MO, USA; Department of Surgery, Washington University in St Louis, St Louis, MO, USA

Zhengjun Zhang

Department of Mathematics, Washington University in St Louis, St Louis, MO, USA

Background When the efficacy of a treatment in a randomized controlled trial is required for multiple primary endpoints, trial design and analysis differ from trial requiring efficacy in only one of the multiple endpoints.

Methods We consider a two-arm clinical trial requiring efficacy analysis for multiple primary endpoints, formulating the appropriate null and alternative hypotheses for the test of treatment efficacy. We study the significance level/statistical power of an intersection-union test (IUT) in this situation. We compare IUT with the intuitive approach (selecting the maximum sample size over those obtained from testing individual primary endpoints one by one) for determination of sample size.

Results The proposed IUT reserves the same Type I error rate as shared by all endpoint-specific tests. The statistical power of the proposed IUT is no more than the minimum from the individual tests. The maximum sample size from multiple endpoint-specific tests is often inadequate for the test of treatment efficacy, especially when the standardized effect sizes are similar. Finally, the IUT can be applied to Alzheimer's disease treatment trials in which two primary endpoints are typically used.

Conclusions The IUT is a valid method for use in the design and analysis of clinical trials requiring efficacy at multiple primary endpoints.

Clinical Trials, Vol. 2, No. 5, 387-393 (2005)
DOI: 10.1191/1740774505cn112oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?